Related Experiment Video

Updated: May 11, 2026

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises

J Besseling1, G K Hovingh, E S G Stroes

  • 1Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands.

The Netherlands Journal of Medicine
|May 29, 2013
PubMed

Insights

Antisense oligonucleotides (ASOs) offer a novel approach to managing dyslipidemia and cardiovascular disease (CVD) by targeting specific mRNA to reduce protein production, addressing residual risk.

Area of Science:

  • Cardiovascular Medicine
  • Molecular Biology
  • Pharmacology

Background:

  • Dyslipidemia is a major risk factor for cardiovascular disease (CVD).
  • Current lipid-lowering therapies reduce CVD risk by ~30%, leaving significant residual risk.
  • Novel therapeutic strategies are needed to further mitigate cardiovascular risk.

Purpose of the Study:

  • To review the current developments in antisense oligonucleotide (ASO) therapy for lipid disorders.
  • To highlight ASOs as a promising new treatment modality for dyslipidemia.
  • To explore the mechanism of ASO action in modulating lipid metabolism.

Main Methods:

  • Literature review of current research on ASO therapy in lipid disorders.
  • Summary of identified ASO targets based on lipid metabolism pathways.
  • Explanation of the mechanism of action for antisense oligonucleotides.

Main Results:

  • ASOs are short DNA strands that degrade specific messenger RNA (mRNA) intracellularly.
  • This process inhibits the production of target proteins involved in lipid metabolism.
  • ASO therapy has emerged as an effective new treatment for dyslipidemia.
  • Several targets for ASO therapy have been identified within lipid metabolism.

Conclusions:

  • ASO therapy represents a significant advancement in managing dyslipidemia and reducing cardiovascular risk.
  • By targeting specific mRNA, ASOs offer a precise mechanism for modulating lipid levels.
  • Further development of ASO therapies holds promise for addressing the unmet needs in cardiovascular risk management.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
What are Lipids?01:38

What are Lipids?

Overview
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...